New Zealand Formulary
Menu Close Menu

Fewer cancers.
Better survival.
Equity for all.

Systemic Anti-Cancer Therapy Regimen Library

Home > BR Metastatic - Abraxane [PACLItaxel nanoparticle albumin bound] [Q1W 2/3]

BR Metastatic - Abraxane [PACLItaxel nanoparticle albumin bound] [Q1W 2/3]

Treatment Overview

Cycle 1 (and all further cycles) - 21 days

Cycle length:
21

Cycle details

Cycle 1 (and all further cycles) - 21 days

Medication Dose Route Days Max Duration
ondansetron 8 mg oral administration 1, 8
Abraxane * 100 mg/m² intravenous 1, 8 30 minutes
domperidone 10 mg Three times daily oral administration 1

Full details

Cycle 1 (and all further cycles) - 21 days

Day: 1

Medication Dose Route Max duration Details
ondansetron 8 mg oral administration
Instructions:
ONE hour prior to chemotherapy. Alternative is dexamethasone 4 mg.
Abraxane * 100 mg/m² intravenous 30 minutes
Instructions:
Do not administer via an in-line filter with a pore size of less than 15 micron.
domperidone 10 mg Three times daily oral administration
Instructions:
When required for nausea and/or vomiting. The choice of rescue antiemetic may be substituted to reflect institutional policy or individual patient characteristics.

Day: 8

Medication Dose Route Max duration Details
ondansetron 8 mg oral administration
Instructions:
ONE hour prior to chemotherapy. Alternative is dexamethasone 4 mg.
Abraxane * 100 mg/m² intravenous 30 minutes
Instructions:
Do not administer via an in-line filter with a pore size of less than 15 micron.

Supportive Care Factors

Factor Value
Emetogenicity: Low

References

Gradishar, W. J., D. Krasnojon, S. Cheporov, et al. 2009. "Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer." J Clin Oncol 27(22):3611-3619, PMID: 19470941

Rugo, H. S., W. Barry, A. Moreno-Aspitia, et al. 2012. "CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC)." ASCO Meeting Abstracts, 30, CRA1002, PMID: 26056183

Gradishar, W. J., Krasnojon, D. & Cheporov, S. 2012."Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival." Clin Breast Cancer; 12 (5): 313-21, PMID: 22728026

Rugo, H. S., W. T. Barry, A. Moreno-Aspitia, et al. 2015. "Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance)." J Clin Oncol 33(21):2361-2369, PMID: 26056183

Gradishar, W. J., D. Krasnojon, S. Cheporov, et al. 2011. "nab-Paclitaxel versus Docetaxel for the first-line treatment of metastatic breast cancer (MBC): Final overall survival (OS) analysis of a randomized phase II trial." ASCO 2011 Breast Cancer Symposium, PMID: 22728026

Regimen details sometimes vary slightly from the published literature after recommendation by expert committee consensus.

* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.

s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.